查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
全球平坦部扁平炎治療市場 -2023-2030
市場調查報告書
商品編碼
1374778

全球平坦部扁平炎治療市場 -2023-2030

Global Pars Planitis Treatment Market -2023-2030
出版日期: | 出版商: DataM Intelligence | 英文 186 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

概述

多年來，全球扁平部炎治療市場經歷了顯著的成長和轉變，影響其動態的因素有很多。稱為平坦部炎的持續性中間葡萄膜炎與任何全身性疾病或感染無關。儘管扁平部炎患者很少出現症狀，但他們可能會提到飛蚊症或視力受損。通常沒有疼痛或畏光。

政府的投資和研究，特別是在發展中經濟體，將繼續推動皮質類固醇或免疫抑制劑等新藥的使用，並推動全球扁平部扁平炎治療市場的發展。幾位研究人員正在開發相應的創新療法，目前正在試驗中。

市場動態：促進因素與限制因素

不斷成長的融資和收購

在高投資、收入水準和基礎設施發展的推動下，已開發經濟體的醫療保健產業不斷改善。由於研究不斷增加，一些國家對扁平部扁平炎治療的需求很大。不同國家之間的各種合作、收購和技術進步的產品發布將是推動市場成長的關鍵因素。

2023年7月3日，Viatris的全球生物相似藥業務最近被Biocon Biologics收購，該公司還在美國、歐洲和其他100多個國家獲得了許多生物相似藥許可證。由於收購了 Viatris 的生物相似藥業務，Biocon Biologics 現在可以幫助為患者和醫療專業人員提供額外的方便且廉價的治療替代方案。

在歐洲使用五年和在加拿大使用兩年後，Biocon Ltd 旗下子公司Biocon Biologics Ltd (BBL) 宣布HULIO (adalimumab-fkjp) 注射劑，一種修美樂(adalimumab) 的生物學名藥，已可供以下國家的患者使用：美國。

此外，出於多種開發目的，擴大利用高水平研究的新技術。扁平部扁平炎病例的增加和創新治療開發研究的增加將是推動扁平部扁平炎治療市場成長的主要因素。

與扁平部炎治療藥物相關的副作用

無論採取何種治療方法，患有平坦部炎的患者患多發性硬化症的可能性都更大，且抗 TNF 藥物可能導致脫髓鞘。因此，在對扁平部炎患者使用抗 TNF 藥物之前，應格外謹慎並評估風險效益比。

扁平部炎也可以用乾擾素成功治療，但副作用可能包括憂鬱或自殺念頭。白內障和青光眼是最常使用的類固醇的副作用。

目錄

第 1 章：方法與範圍

  • 研究方法論
  • 報告的研究目的和範圍

第 2 章：定義與概述

第 3 章：執行摘要

  • 藥物片段
  • 依給藥途徑分類
  • 按配銷通路分類
  • 按地區分類

第 4 章：動力學

  • 影響因素
    • 促進要素
      • 不斷成長的融資和收購
      • 不斷進步的技術進步與發展
    • 限制
      • 與扁平部炎藥物相關的副作用
    • 機會
    • 影響分析

第 5 章：產業分析

  • 波特五力分析
  • 供應鏈分析
  • 定價分析
  • 監管分析
  • SWOT分析
  • 專利分析
  • 俄烏戰爭影響分析
  • DMI 意見

第 6 章：COVID-19 分析

  • COVID-19 分析
    • 新冠疫情爆發前的情景
    • 新冠疫情期間的情景
    • 新冠疫情後的情景
  • COVID-19 期間的定價動態
  • 供需譜
  • 疫情期間政府與市場相關的舉措
  • 製造商策略舉措
  • 結論

第7章 ：透過藥物

  • 皮質類固醇
    • 潑尼松（Deltasone、Meticorten、Orasone）
    • 曲安西龍（Amcort）
    • 潑尼松龍 1% (Pred Forte)
  • 免疫抑制劑
    • 甲胺蝶呤（Folex PFS、Rheumatrex）
    • 黴酚酸酯（CellCept、MMF、Myfortic）
    • 環孢素（Sandimmune、Neoral）
    • 硫唑嘌呤（Imuran）
  • 組織胺 H2 受體拮抗劑
    • 西咪替丁（泰胃美）
    • 雷尼替丁（Zantac）
  • 胃泵抑制劑
    • 奧美拉唑（Prilosec）
    • 蘭索拉唑（Prevacid）
    • 埃索美拉唑鎂（Nexium）
  • 腫瘤壞死因子 (TNF) 抑制劑 (DMARD)
    • 阿達木單抗（阿達木單抗-atto、Amjevita、Humira）

第 8 章：依給藥途徑分類

  • 口服
  • 靜脈
  • 其他

第 9 章：按配銷通路

  • 醫院藥房
  • 零售藥局
  • 網路藥局

第 10 章：按地區

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 義大利
    • 西班牙
    • 歐洲其他地區
  • 南美洲
    • 巴西
    • 阿根廷
    • 南美洲其他地區
  • 亞太
    • 中國
    • 印度
    • 日本
    • 澳洲
    • 亞太其他地區
  • 中東和非洲

第 11 章：競爭格局

  • 競爭場景
  • 市場定位/佔有率分析
  • 併購分析

第 12 章：公司簡介

  • Teva Pharmaceutical Industries Ltd.
    • 公司簡介
    • 產品組合和描述
    • 財務概覽
    • 主要進展
  • AbbVie Inc. (Allergan)
  • Aurobindo Pharma USA
  • Pfizer Inc.
  • Genentech, Inc.
  • Novartis AG
  • Rosemont Pharmaceuticals Limited
  • Xiromed
  • Takeda Pharmaceutical Company Limited
  • Boehringer Ingelheim Pharmaceuticals, Inc.

第 13 章：附錄

簡介目錄
Product Code: PH7183

Overview

The global pars planitis treatment market has witnessed significant growth and transformations over the years, with various factors influencing its dynamics. A persistent intermediate uveitis called pars planitis has not been connected with any systemic illness or infection. Although pars planitis patients rarely experience symptoms, they could mention floaters or impaired vision. There is typically no pain or photophobia.

Government investments and research, particularly in developing economies, will continue to drive utilization of novel medicines like corticosteroids or immunosuppressives and boost the global pars planitis treatment market. The respective innovative treatment are being developed by several researchers and currently are under trials.

Market Dynamics: Drivers & Restraints

Growing funding and acquisitions

Developed economies have been witnessing rapid growth in betterment of their healthcare sectors, driven by high investments, income levels, and infrastructure development. Several countries have experienced substantial demand for pars planitis treatment owing to the rising research. Various collaborations, acquisitions and product launches with technological advanecments among different countries will be a crucial factor driving the growth of the market.

On July 3, 2023, the global biosimilars business of Viatris was recently acquired by Biocon Biologics, which has also obtained numerous biosimilar licenses in the United States, Europe, and more than 100 other nations. Biocon Biologics can now assist in supplying patients and medical professionals with additional accessible and inexpensive treatment alternatives thanks to the acquisition of Viatris' biosimilars business.

After five years of use in Europe and two years in Canada, Biocon Biologics Ltd (BBL), a division of Biocon Ltd, announced that HULIO (adalimumab-fkjp) injectable, a biosimilar to Humira (adalimumab), has become accessible to patients in the United States.

Furthermore, the rising utilization of novel technology with high level of research for the several development purposes. Rising pars planitis cases and increasing research for innovative treatment development will be a major factor driving the growth of the pars planitis treatment market.

Side effects associated with the pars planitis treatment drugs

Regardless of treatment, patients with pars planitis could be at a greater likelihood for getting multiple sclerosis and anti-TNF Drugs may predispose to demyelination. Therefore, utmost caution should be utilized and the risk-benefit ratio should be assessed before administering an anti-TNF drug to a patient with pars planitis.

Pars planitis has also been successfully treated with interferon, however side effects can include depression or suicidal thoughts. Cataracts and glaucoma are the side effects of steroids that are most frequently administered.

Segment Analysis

The global pars planitis treatment market is segmented based on drugs, route of administration, distribution channel and region.

Corticosteroids segment accounted for approximately 37% of market share

Prednisolone sodium phosphate or acetate topical treatment, both of which are 1%. Along with oral prednisone, periocular injections with corticosteroids are also beneficial. Treatment options include intravitreal injections of triamcinolone acetonide.

Steroid medications can be used to treat the majority of intermediate uveitis cases. Prednisolone is a medication that is frequently used. Steroids act by interfering with the immune system's regular operation so that it no longer secretes the substances that cause inflammation.

On November 17, 2021, the U.S. Food and Drug Administration has given final approval to Aurobindo Pharma Limited's Abbreviated New Drug Application for Prednisone Tablets USP, 1mg. Prednisone Tablets USP, 1mg from Aurobindo Pharma are a reference-listed drug (RLD) identical to Meticorten Tablets from Schering Corp Sub Schering Plough Corp.

Geographical Penetration

North America accounted for around 36% of market share in 2022

Due to the rising need for pars planitis treatment in healthcare, manufacturers in North America have chances of increasing their operations. There are many producers and suppliers in North America and owing to the quick economic growth of the region, industrial production has expanded, driving the demand for pars planitis treatment.

Increasing expenditure on healthcare and rising research studies, advancement of technologies and different classes of drug, and increase in biopharmaceutical or biotechnology business establishment across the region are also contributing to the growth of pars planitis treatment market share of this region. The market in this area is growing as people become more aware of various novel approved medicines. The aforementioned elements further attest to North America's hegemonic position in the world.

North America continues to be a key player in the global pars planitis treatment market, with United States leading the way. Government initiatives promoting infrastructure development and investment, and a focus on rising advancements have fueled the demand for pars planitis treatment in the U.S. United States have been proactive in executing several initiatives or researches, stimulating pars planitis treatment demand.

COVID-19 Impact Analysis

The outbreak of the COVID-19 pandemic in late 2019 created unprecedented challenges for industries worldwide, including the global pars planitis treatment market. As countries grappled with lockdowns, supply chain disruptions and reduced economic activity, the pharmaceutical sector, with a significant consumer of various medicines, was significantly impacted. Several efforts all throughout the world were impacted by the pandemic's broad lockdowns and limitations that started in early 2020.

Major medical and pharmaceutical industries came to a standstill and shifted their attention towards the management of COVID-19, leading to a slump in demand for pars planitis treatment. Now several research studies have been initiated and companies have again started trial for their products efficiency. Overall, the impact of the pandemic on the global pars planitis treatment market is expected to be relatively moderate, with the market continuing to grow steadily due to the ongoing need and research for inovative treatment.

Key Developments

  • On March 21, 2023, the US Food and Drug Administration (FDA) has approved a high-concentration formulation (HCF) which is citrate-free of Sandoz's biosimilar Hyrimoz (adalimumab-adaz) injection, according to the company, a leader in generic drugs and biosimilars. The reference drug Humira* (adalimumab) covers seven indications, including rheumatoid arthritis, psoriatic arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, ulcerative colitis, Crohn's disease, and plaque psoriasis. The adalimumab citrate-free HCF (100 mg/mL) is approved to treat these conditions.
  • On March 25, 2021, Omeprazole Prolonged Release Capsules, 20mg, a generic version of Prilosec, have been launched, according to Xiromed LLC, the generic branch of Insud Pharmaceuticals based in New Jersey. Proton pump inhibitors like Prilosec are prescribed for treating gastroesophageal reflux disease (GERD) in both adults and children as well as for treating duodenal and gastric ulcers in adults and maintaining the healing of erosive esophagitis.

Competitive Landscape

The major global players in the market include: Teva Pharmaceutical Industries Ltd., AbbVie Inc. (Allergan), Aurobindo Pharma USA, Pfizer Inc., Genentech, Inc., Novartis AG, Rosemont Pharmaceuticals Limited, Xiromed, Takeda Pharmaceutical Company Limited and Boehringer Ingelheim Pharmaceuticals, Inc. among others.

Why Purchase the Report?

  • To visualize the global pars planitis treatment market segmentation based on drugs, route of administration, distribution channel and region as well as understand key commercial assets and players.
  • Identify commercial opportunities by analyzing trends and co-development.
  • Excel data sheet with numerous data points of pars planitis treatment market-level with all segments.
  • PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
  • Product mapping available as excel consisting of key products of all the major players.

The global pars planitis treatment market report would provide approximately 61 tables, 59 figures and 186 Pages.

Target Audience 2023

  • Manufacturers/ Buyers
  • Industry Investors/Investment Bankers
  • Research Professionals
  • Emerging Companies

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

  • 3.1. Snippet by Drugs
  • 3.2. Snippet by Route of Administration
  • 3.3. Snippet by Distribution Channel
  • 3.4. Snippet by Region

4. Dynamics

  • 4.1. Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Growing funding and acquisitions
      • 4.1.1.2. Rising technological advancements and developments
    • 4.1.2. Restraints
      • 4.1.2.1. Side effects associated with the pars planitis drugs
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Force Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Pricing Analysis
  • 5.4. Regulatory Analysis
  • 5.5. SWOT Analysis
  • 5.6. Patent Analysis
  • 5.7. Russia-Ukraine War Impact Analysis
  • 5.8. DMI Opinion

6. COVID-19 Analysis

  • 6.1. Analysis of COVID-19
    • 6.1.1. Scenario Before COVID
    • 6.1.2. Scenario During COVID
    • 6.1.3. Scenario Post COVID
  • 6.2. Pricing Dynamics Amid COVID-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturers Strategic Initiatives
  • 6.6. Conclusion

7. By Drugs

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drugs
    • 7.1.2. Market Attractiveness Index, By Drugs
  • 7.2. Corticosteroids*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
    • 7.2.3. Prednisone (Deltasone, Meticorten, Orasone)
    • 7.2.4. Triamcinolone (Amcort)
    • 7.2.5. Prednisolone 1% (Pred Forte)
  • 7.3. Immunosuppressives
    • 7.3.1. Methotrexate (Folex PFS, Rheumatrex)
    • 7.3.2. Mycophenolate (CellCept, MMF, Myfortic)
    • 7.3.3. Cyclosporine (Sandimmune, Neoral)
    • 7.3.4. Azathioprine (Imuran)
  • 7.4. Histamine H2-Receptor Antagonist
    • 7.4.1. Cimetidine (Tagamet)
    • 7.4.2. Ranitidine (Zantac)
  • 7.5. Gastric Pump Inhibitors
    • 7.5.1. Omeprazole (Prilosec)
    • 7.5.2. Lansoprazole (Prevacid)
    • 7.5.3. Esomeprazole magnesium (Nexium)
  • 7.6. Tumor Necrosis Factor (TNF) inhibitors (DMARDs)
    • 7.6.1. Adalimumab (Adalimumab-atto, Amjevita, Humira)

8. By Route of Administration

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 8.1.2. Market Attractiveness Index, By Route of Administration
  • 8.2. Oral *
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 8.3. Intravenous
  • 8.4. Others

9. By Distribution Channel

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 9.1.2. Market Attractiveness Index, By Distribution Channel
  • 9.2. Hospital Pharmacies*
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 9.3. Retail Pharmacies
  • 9.4. Online Pharmacies

10. By Region

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 10.1.2. Market Attractiveness Index, By Region
  • 10.2. North America
    • 10.2.1. Introduction
    • 10.2.2. Key Region-Specific Dynamics
    • 10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drugs
    • 10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.2.6.1. U.S.
      • 10.2.6.2. Canada
      • 10.2.6.3. Mexico
  • 10.3. Europe
    • 10.3.1. Introduction
    • 10.3.2. Key Region-Specific Dynamics
    • 10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drugs
    • 10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.3.6.1. Germany
      • 10.3.6.2. UK
      • 10.3.6.3. France
      • 10.3.6.4. Italy
      • 10.3.6.5. Spain
      • 10.3.6.6. Rest of Europe
  • 10.4. South America
    • 10.4.1. Introduction
    • 10.4.2. Key Region-Specific Dynamics
    • 10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drugs
    • 10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.4.6.1. Brazil
      • 10.4.6.2. Argentina
      • 10.4.6.3. Rest of South America
  • 10.5. Asia-Pacific
    • 10.5.1. Introduction
    • 10.5.2. Key Region-Specific Dynamics
    • 10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drugs
    • 10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.5.6.1. China
      • 10.5.6.2. India
      • 10.5.6.3. Japan
      • 10.5.6.4. Australia
      • 10.5.6.5. Rest of Asia-Pacific
  • 10.6. Middle East and Africa
    • 10.6.1. Introduction
    • 10.6.2. Key Region-Specific Dynamics
    • 10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drugs
    • 10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel

11. Competitive Landscape

  • 11.1. Competitive Scenario
  • 11.2. Market Positioning/Share Analysis
  • 11.3. Mergers and Acquisitions Analysis

12. Company Profiles

  • 12.1. Teva Pharmaceutical Industries Ltd.*
    • 12.1.1. Company Overview
    • 12.1.2. Product Portfolio and Description
    • 12.1.3. Financial Overview
    • 12.1.4. Key Developments
  • 12.2. AbbVie Inc. (Allergan)
  • 12.3. Aurobindo Pharma USA
  • 12.4. Pfizer Inc.
  • 12.5. Genentech, Inc.
  • 12.6. Novartis AG
  • 12.7. Rosemont Pharmaceuticals Limited
  • 12.8. Xiromed
  • 12.9. Takeda Pharmaceutical Company Limited
  • 12.10. Boehringer Ingelheim Pharmaceuticals, Inc.

LIST NOT EXHAUSTIVE

13. Appendix

  • 13.1. About Us and Services
  • 13.2. Contact Us